{"id":389008,"date":"2024-12-20T00:00:00","date_gmt":"2024-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0014-2024-biopharma-iga-nephropathy-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:38","modified_gmt":"2026-03-31T10:27:38","slug":"dlsfmd0014-2024-biopharma-iga-nephropathy-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0014-2024-biopharma-iga-nephropathy-disease-landscape-forecast-g7-2024\/","title":{"rendered":"IgA Nephropathy | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>Immunoglobulin A nephropathy (IgAN), or Berger\u2019s disease, is an autoimmune disease that causes galactose-deficient IgA1 (Gd-IgA1) to accumulate in the kidney glomeruli, impairing their blood filtration function. Supportive care for IgAN, such RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and diuretics, plays a major role in slowing the disease\u2019s progression. Calliditas Therapeutics\u2019 Tarpeyo \/ Kinpeygo (delayed-release budesonide) and Travere Therapeutics\u2019 Filspari (sparsentan) are approved to treat IgAN. Over the 2023-2033 forecast period, the IgAN therapy market will experience significant growth owing to the emergence of novel therapeutic pathways, such as complement factor B inhibition (e.g., Novartis\u2019s Fabhalta [iptacopan], Roche\u2019s RO7434656), APRIL and\/or BAFF inhibition (e.g., Otsuka\u2019s sibeprenlimab, Novartis\u2019s zigakibart, Vera Therapeutics\u2019 atacicept), and angiotensin and\/or endothelin receptor antagonism (e.g., Novartis\u2019s atrasentan). Supported by insights from thought leaders, we analyze the challenges and opportunities treating this complex disease.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What percentage of the IgAN population receive drug treatment? How do physicians use current therapies to treat the disease?<\/li>\n<li>Where will Tarpeyo \/ Kinpeygo and Filspari (sparsentan) be positioned in the evolving IgAN treatment landscape? Which emerging therapies do experts find most promising, and how will they influence future prescribing patterns?<\/li>\n<li>Which unmet needs will the emerging therapies be able to fulfill?<\/li>\n<li>What access and reimbursement challenges are the emerging therapies anticipated to face upon market entry?<\/li>\n<\/ul>\n<p><strong>SCOPE<\/strong><\/p>\n<ul>\n<li><strong>Geography:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan<\/li>\n<li><strong>Primary research:<\/strong> 19 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research<\/li>\n<li><strong>Epidemiology:<\/strong> Diagnosed prevalent and drug-treated cases of IgA nephropathy by country and age groups<\/li>\n<li><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key IgA nephropathy therapies through 2033, segmented by brands \/ generics and epidemiological subpopulations<\/li>\n<li><strong>Emerging therapies:<\/strong> Phase 3\/PR: 6 drugs; Phase 2: 7 drugs; coverage of select early-phase products<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389008","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389008\/revisions"}],"predecessor-version":[{"id":575856,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389008\/revisions\/575856"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}